Clinical Significance of Follistatin in Obese and Non-obese Egyptian Polycystic Ovarian Patients

2016-03-20T18-37-12Z
Source: Journal of Molecular Pathophysiology
Mostafa El-Shafey, Maghawry Hegazy, Mohammed El-Zahabi, Mohammed Farahat.
Abstract: Objective: Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders in women, characterized by hyperandrogenism, infertility, chronic oligo or an ovulation and obesity. In this present study we investigate the level of follistatin in obese and non-obese women with PCOS and define any correlation between follistatin and hormonal parameters. Methods: The study group included 23 obese and 17 non-obese PCOS patients. The control group included 18 obese and 22 non-obese subjects. Blood samples were obtained from the patients on day 25 of menstrual cycle and were assayed for Leutinizing hormone (LH), follicle stimulating hormone (FSH), total testosterone, follistatin, prolactin, sex hormone binding globulin (SHBG) and fasting insulin using enzyme-linked immunosorbent assays (ELISA), fasting glucose was measured spectrophotometry. Hemostasis model assessment - insulin resistance (HOMA-IR), free androgen index (FAI), LH/FSH ratio were calculated. Results: Follistatin concentrations were significantly higher in obese and non-obese PCOS patients (mean ± SE; 1207 ± 37.99 and 1106 ± 30.8 pg /ml respectively) than their respective controls (721.9 ± 23.44and 653.3± 25.88pg./ml, P

from Scope via xlomafota13 on Inoreader http://ift.tt/1VsJgig
via IFTTT